Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $111.84, for a total transaction of $782,880.00. Following the completion of the sale, the insider owned 32,718 shares in the company, valued at approximately $3,659,181.12. This trade represents a 17.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Monday, June 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.28, for a total value of $550,568.16.

Oruka Therapeutics Stock Up 0.4%

Shares of Oruka Therapeutics stock opened at $113.08 on Wednesday. The firm has a market cap of $7.49 billion, a P/E ratio of -55.70 and a beta of -0.34. Oruka Therapeutics, Inc. has a fifty-two week low of $14.08 and a fifty-two week high of $113.31. The business has a 50-day moving average price of $89.42 and a 200 day moving average price of $63.91.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, equities research analysts anticipate that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ORKA shares. HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Monday, August 3rd. Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, April 30th. Piper Sandler reissued an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. UBS Group increased their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Finally, Guggenheim reaffirmed a “buy” rating and issued a $200.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Oruka Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $134.30.

Institutional Trading of Oruka Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Sei Investments Co. boosted its holdings in shares of Oruka Therapeutics by 136.0% during the first quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock valued at $1,120,000 after acquiring an additional 13,164 shares during the period. Moody Aldrich Partners LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter worth about $3,844,000. Dimensional Fund Advisors LP bought a new stake in Oruka Therapeutics in the 1st quarter valued at about $5,543,000. Handelsbanken Fonder AB bought a new stake in Oruka Therapeutics in the 2nd quarter valued at about $15,313,000. Finally, The Manufacturers Life Insurance Company lifted its position in Oruka Therapeutics by 18.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock valued at $3,559,000 after purchasing an additional 11,205 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.